StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Rajesh Satpute

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byRajesh SatputeHorizon: BTST7 Aug 2026, 8:36 am ISTvia CNBC Awaaz.

Entry₹2,274.9Inferred
Target₹2,340
Total upside +2.86% (call closed)
Stop loss₹2,270-0.22% risk
Exit₹2,2707 Aug 2026, 9:15 am
Stop-loss hit-0.22%
Follow Rajesh Satpute for new calls(8% target hit, 124 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 3 active BTST picks this session

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 7 Aug 2026
4 supporting2 neutral0 opposing
Supports the BUY call (4)

1 advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·6 Aug · yesterday

Glenmark Pharma's India-US Growth Story Intact, Says Motilal Oswal, Maintaining 'Buy' — Check Target Price

NewsNdtv-Profit·4 Aug · 3d ago

(opens in new tab)

Glenmark Pharma Q1 profit jumps over 10-fold as India, North America businesses power growth

NewsCnbc-Tv18·31 Jul · 6d ago

(opens in new tab)

Glenmark Pharma Q1 Results: Profit Rises Exponentially To Rs 483 Crore; Revenue Jumps 23%

NewsNdtv-Profit·31 Jul · 6d ago

(opens in new tab)
Neutral / worth noting (2)

Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·31 Jul · 6d ago

(opens in new tab)

The Board of Directors has considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026

BSE · Board Meeting·31 Jul · 6d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Rajesh Satpute

Every call and its outcome